
Clinical Trials & eTMF
Trial platforms (eTMF, IRT/IWRS, site management) on Veeva Vault or bespoke, validated end to end.
Clinical platforms, pharmacovigilance, eCTD submissions, and discovery AI, shipped by senior teams from inside Tier-1 pharma, CDMOs, and CROs.

Build, validate, and run the full pharma estate under a single accountable senior pod.

Trial platforms (eTMF, IRT/IWRS, site management) on Veeva Vault or bespoke, validated end to end.

ePRO and eCOA capture wired into Medidata Rave, Oracle Clinical, and OpenClinica, GCP-validated, audit-trailed.

ICSR intake, signal detection, and aggregate reporting, Argus and ArisGlobal, aligned to E2B(R3) and MedDRA.

Auto-publishing eCTD platforms with FDA/EMA gateway integration, IND, NDA, MAA, and BLA, lifecycle-managed.

Validated lakes, SDTM/ADaM pipelines, and full lineage, every CSR figure traceable to source.

Target ID, generative chemistry, ADMET prediction, and trial AI, with eval harnesses and model-risk packs.
Every BritonOne Technology pharma programme ships its validation pack, audit trail, and 21 CFR Part 11 evidence alongside the code, not three months after the inspection. The result: 42% faster study start-up, zero FDA Form 483 observations on engineered systems, and submissions that clear EMA on first read.
IQ/OQ/PQ scrambled the month before audit, and findings repeat at every inspection cycle.
Bespoke site builds, paper-heavy training, and manual CRF programming bottleneck every study.
Statisticians map raw CRF data to SDTM weeks before lock; errors surface in the CSR review.
ICSRs queue for manual coding; aggregate reports miss windows; agencies escalate.
Audit trails, electronic signatures, and validation evidence emit per release, every build is inspection-ready.
Templated study builds, automated CRF generation, and pre-validated components compress start-up.
Mappings live as code, gated in CI, regenerated on every CRF change, lock cycles drop by weeks.
MedDRA auto-coding, signal detection in-pipeline, and aggregate reports generated on demand.
Selected programmes across Tier-1 pharma, speciality, CDMOs, CROs, and emerging biotech, anonymised where required, specific on the outcome.
Production RAG over clinical study reports, regulatory submissions, and target labels, 4,200 medical writers and regulatory affairs colleagues live on the platform. Validation pack and 21 CFR Part 11 audit trail shipped alongside the build; cleared model risk on first review. Document drafting time cut by half across CSR, IB, and protocol templates.

ICSR intake, MedDRA auto-coding, and signal detection rebuilt, agency windows met without overtime.

Templated study builds with auto-CRF generation, site activation in days, not months.

Bidirectional MES/LIMS wiring with batch-record automation, GMP audit trail captured at every step.

HIPAA + GDPR-grade patient portal with adherence tracking and HCP messaging.

EDC, eCRF, ePRO, eConsent, and randomisation on one validated platform, with medical coding to WHODrug and MedDRA and an audit trail per subject, stood up in a single quarter for a Phase III programme.

Production integrations across every major pharma estate: clinical, regulatory, safety, and quality on one GxP-clean surface.
Connected. Unified. Audit-ready.
Audit trails, e-signatures, and CSV evidence emit per release, every build is inspection-ready, not retrofitted.
Mappings live in the repo, gated in CI, regenerated on every CRF change, no late-stage scramble to lock before the CSR.
IQ/OQ/PQ, traceability matrices, and risk assessments emit per release, QA reviews evidence that already exists.
Every engagement walks the same path, sized to your problem, but with the same verification gates baked in.
Two-week paid sprint. Architect-led. Output: regulator map, costed roadmap, signed scope.
Pod composition, sequenced milestones, change-control governance, and risk register.
Reference architecture, threat model, design system, and acceptance criteria locked.
Weekly demos, trunk-based, CI/CD from day one. Code reviewed against spec at every gate.
Unit, integration, e2e, security, performance, and accessibility, automated and gated.
Blue-green or canary, observability live before launch, rollback rehearsed.
Managed services or hypercare hand-off. Defined SLOs, named on-call, monthly reviews.
Success stories
BritonOne Technology is a full-cycle engineering company that builds and operates production software for regulated estates. Since 2017, we have shipped programmes that clear audit on the first pass across banking, insurance, wealth, healthcare, and biotech. Our teams pair deep domain knowledge with disciplined engineering, treating compliance, security, and resilience as first-class deliverables. From architecture through to live operations, we stay accountable for the systems we build, measuring success by uptime, audit outcomes, and defensible business results.
We don't compete on lowest day-rate. We compete on shipped outcomes inside environments that have to clear audit.
Every engineer on every engagement is at least senior, typically eight to fifteen years deep in their craft. No bench rotations, no junior pyramid hidden behind a glossy proposal, no bait-and-switch after contract signature. The architect who scoped your engagement is the same person committing code by week three.
FCA, PRA, EBA, BaFin, FINMA, HIPAA, SOC 2 Type II: every framework we work under is treated as a design constraint from day one, not a final-stage gate. Evidence trails, model-risk packs, change-control artefacts, and pen-test reports ship alongside the code, ready for second-line review without a remediation sprint.
Small pods of three to seven engineers, each with a named delivery lead who owns scope, schedule, and outcomes from kickoff to hand-off, never a faceless team you have to chase for an answer. Weekly demos run against the signed scope, frequent verification gates catch regressions early, and quarterly outcome reviews measure real progress against the original business case rather than a moving target. Together those rituals catch scope drift before it has any chance to compound, so programmes that should take six months don't quietly stretch into eighteen, budgets stay anchored to what was agreed, and every milestone ships with a written, testable definition of done that both sides sign off before we move on.
We don't disappear the moment the engagement closes. Managed services, hypercare windows, named on-call rotations, or quarterly health checks: pick the depth that matches your operational risk profile. About seventy percent of clients return for a second programme, usually because the team that shipped the first one is still on the other end of the page.
Anonymous under MNDA. Each quote is from a senior pharma buyer who owned the engagement end to end.
“First clinical platform of mine that cleared an FDA Part 11 inspection on the first attempt. The validation pack and audit trail were ready before the inspector walked in.”
Direct answers to what procurement, security, and delivery leads weigh before signing: compliance, integration, and the accountability we put in writing.
Yes. We engineer to 21 CFR Part 11 and EU Annex 11 from day one, electronic signatures, audit trails, access controls, and computer system validation are first-class deliverables, not retrofitted before the inspection. We ship the IQ/OQ/PQ pack alongside each release and sit with your QA team through validation review.